Latest:
Future Directions in the Management of Immune Thrombocytopenia
Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sylvie Bonvalot, MD, PhD, HDR
Latest:
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Nagla Abdel Karim, MD
Latest:
Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLC
Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.
B. Douglas Smith, MD
Latest:
Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial
Dr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.
Nataliya V. Uboha, MD, PhD, University of Wisconsin Carbone Cancer Center
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer
Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.